New peer-reviewed publication with the results of apceth Biopharma’s TREAT-ME 1 clinical trial

This phase I/II, first-in-class, first-in-men clinical trial tested safety, tolerability and efficacy of genetically modified mesenchymal stem cells (MSC) in the treatment of advanced, recurrent gastrointestinal cancer.

Download publication:

Publication_apceth Biopharma_TREAT-ME 1 clinical trial

Please note: today apceth Biopharma focuses solely on the CDMO business